CorEvitas Generalized Pustular Psoriasis (GPP) Drug Safety and Effectiveness Registry

NCT06100991 | Recruiting

• 1 other identifier: GPP-510
• Study Type: observational
• Target: 200
• Locations: 1 country
• Sites: 1

Brief Summary

Prospective, observational registry for subjects with GPP under the care of a dermatology investigator.Approximately 200 subjects and 75 clinical sites in North America will be recruited to participate with no defined upper limit for either target

Conditions

Generalized Pustular Psoriasis

Outcome Measures

Primary Outcomes (2)

• Primary Outcome Measure:GPP epidemiology and Presentation

  The major clinical outcomes include an assessment of the epidemiology of GPP; to better understand the presentation and natural history.

  Through study completion, an average of 10 years

• GPP management, and outcomes

  The major clinical outcome include an assessment of the epidemiology of GPP; to better understand the management and outcomes.

  Through study completion, an average of 10 years

Study Arms (1)

Generalized Pustular Psoriasis (GPP)

Pts presenting to enrolling sites across the North America are invited to enroll if eligible

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Subjects are enrolled in the GPP Registry during regularly scheduled office visits. Selected dermatologists are invited to participate as investigators in the Registry.

You may qualify if:

• A subject must meet all the following criteria to participate in the registry:
• Has been diagnosed with GPP by a dermatologist or a qualified dermatology practitioner.
• Is at least 18 years of age and has attained the legal age for consent to procedures involved in the research, under the applicable law of the jurisdiction in which the research is being conducted.
• Is willing to provide consent for participation in the registry.
• Is willing to provide Personal Information

You may not qualify if:

• Any of the following would exclude the subject from participating in the registry:
• Is participating or planning to participate in a blinded clinical trial evaluating a systemic agent for the treatment or prevention of flares related to GPP.
• Is enrolled in another CorEvitas registry for a dermatological condition. Subjects enrolled in another CorEvitas registry must be exited to be eligible for enrollment into the GPP Registry

Sponsors & Collaborators

• CorEvitas: lead

Study Sites (1)

CorEvitas, LLC

Waltham, Massachusetts, 02451, United States

RECRUITING

Related Links

• Related Info

MeSH Terms

Conditions

Psoriasis

Condition Hierarchy (Ancestors)

Skin Diseases, Papulosquamous; Skin Diseases; Skin and Connective Tissue Diseases

Central Study Contacts

Cathy Cheney

CONTACT

+1 508 408 5433; corevitasregistrytrials@corevitas.com

Jeffrey Greenberg, MD

CONTACT

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Sponsor Type: NETWORK
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: October 3, 2023
• First Posted: October 25, 2023
• Study Start: September 19, 2023
• Primary Completion (Estimated): December 1, 2099
• Study Completion (Estimated): December 1, 2099
• Last Updated: February 9, 2026

Record last verified: 2025-08

Data Sharing

• IPD Sharing: Will not share

Locations

US (1)